Olanzapine
1: Huang J, Kang D, Zhang F, Yang Y, Liu C, Xiao J, Long Y, Lang B, Peng X, Wang W, Wang X, Liu F, Davis JM, Zhao J, Wu R. Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials. Schizophr Bull. 2022 Jun 21;48(4):850-859. doi: 10.1093/schbul/sbac044. PMID: 35569003; PMCID: PMC9212091.
2: Pawełczyk T, Grancow-Grabka M, Żurner N, Pawełczyk A. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study. Schizophr Res. 2021 Apr;230:61-68. doi: 10.1016/j.schres.2021.02.012. Epub 2021 Mar 5. PMID: 33684737.
3: Bodoano Sánchez I, Fernández-Pérez MD, Molera Manzano D, Gutiérrez-Rojas L, Romero-Fábrega JC. Visual Hallucinations in a Patient With Moyamoya Disease: A Review and Case Report. Cogn Behav Neurol. 2021 Mar 3;34(1):63-69. doi: 10.1097/WNN.0000000000000260. PMID: 33652470.
4: Cabrera-Mendoza B, Martínez-Magaña JJ, Monroy-Jaramillo N, Genis-Mendoza AD, Fresno C, Fries GR, Walss-Bass C, López Armenta M, García-Dolores F, Díaz-Otañez CE, Flores G, Vázquez-Roque RA, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co-expression network- based drug repositioning. Am J Med Genet B Neuropsychiatr Genet. 2021 Apr;186(3):193-206. doi: 10.1002/ajmg.b.32830. Epub 2021 Jan 6. PMID: 33403748.
5: Balcioglu YH, Gokcay H, Yesilkaya UH. One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia. Clin Neuropharmacol. 2020 Sep/Oct;43(5):166-168. doi: 10.1097/WNF.0000000000000404. PMID: 32947430.
6: Yesilkaya UH, Balcioglu YH. Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism. J Clin Psychopharmacol. 2020 Jul/Aug;40(4):412-414. doi: 10.1097/JCP.0000000000001214. PMID: 32433255.
7: Williamson D, Frenette AJ, Burry LD, Perreault M, Charbonney E, Lamontagne F, Potvin MJ, Giguère JF, Mehta S, Bernard F. Pharmacological interventions for agitated behaviours in patients with traumatic brain injury: a systematic review. BMJ Open. 2019 Jul 9;9(7):e029604. doi: 10.1136/bmjopen-2019-029604. PMID: 31289093; PMCID: PMC6615826.
8: Matei VP, Purnichi T, Mihailescu A, Grigoras R. PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS. Acta Endocrinol (Buchar). 2018 Oct-Dec;14(4):483-490. doi: 10.4183/aeb.2018.483. PMID: 31149301; PMCID: PMC6516404.
9: Liang M, Zhang B, Deng L, Xu R, Wu H, Chen J. Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients. Int J Endocrinol. 2019 Mar 21;2019:1312804. doi: 10.1155/2019/1312804. PMID: 31019532; PMCID: PMC6451798.
10: Apap Mangion S, Rugg-Gunn F. Development of forced normalisation psychosis with ethosuximide. BMJ Case Rep. 2017 Dec 7;2017:bcr2017220838. doi: 10.1136/bcr-2017-220838. PMID: 29222216; PMCID: PMC5728201.
11: Roth J. The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S75-S79. doi: 10.1016/j.parkreldis.2017.08.004. Epub 2017 Aug 10. PMID: 28807495.
12: Sagreiya H, Chen YR, Kumarasamy NA, Ponnusamy K, Chen D, Das AK. Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations. Cureus. 2017 Feb 26;9(2):e1059. doi: 10.7759/cureus.1059. PMID: 28465867; PMCID: PMC5409818.
13: Furuta T, Sabit H, Dong Y, Miyashita K, Kinoshita M, Uchiyama N, Hayashi Y, Hayashi Y, Minamoto T, Nakada M. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget. 2017 Apr 4;8(14):22811-22824. doi: 10.18632/oncotarget.15206. PMID: 28423558; PMCID: PMC5410264.
14: Monroy-Jaramillo N, Rodríguez-Agudelo Y, Aviña-Cervantes LC, Roberts DL, Velligan DI, Walss-Bass C. Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine. J Psychiatr Res. 2017 Jul;90:26-30. doi: 10.1016/j.jpsychires.2017.02.007. Epub 2017 Feb 10. PMID: 28226264.
15: Benedict F, Lim KS, Jambunathan ST, Hashim AH. Antiepileptic-induced Psychosis as a Possible Predictor of Post-temporal Lobectomy Alternative Psychosis. East Asian Arch Psychiatry. 2016 Sep;26(3):109-11. PMID: 27703099.
16: Kumagai R, Kitazawa M, Ishibiki Y, Narumi K, Ichimiya Y. A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report. Psychogeriatrics. 2017 May;17(3):202-203. doi: 10.1111/psyg.12208. Epub 2016 Jul 13. PMID: 27405248.
17: Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19. PMID: 25524815.
18: Tatar ZB, Oflaz S, Baran B. A case of late-onset angioedema associated with clozapine and redevelopment of angioedema with olanzapine. J Clin Psychopharmacol. 2014 Aug;34(4):523-5. doi: 10.1097/JCP.0000000000000153. PMID: 24911442.
19: Zhao M, Geng T, Qiao L, Zhang M, Shi J, Huang F, Lin X, Wang J, Zuo H. Olanzapine-induced restless legs syndrome. J Clin Neurosci. 2014 Sep;21(9):1622-5. doi: 10.1016/j.jocn.2014.01.007. Epub 2014 May 27. PMID: 24874697.
20: Bakhtiarian A, Takzare N, Sheykhi M, Sistany N, Jazaeri F, Giorgi M, Nikoui V. Teratogenic effects of coadministration of fluoxetine and olanzapine on rat fetuses. Adv Pharmacol Sci. 2014;2014:132034. doi: 10.1155/2014/132034. Epub 2014 Jan 15. PMID: 24527029; PMCID: PMC3914285.
21: Macrì F, Minichino A, Campi S, Marino M, Pannese R, De Michele F, Capra E, Trabucchi G, Bersani FS. Disturbo di conversione somatico cronicizzato [Chronic conversion somatic disorder: a case report]. Recenti Prog Med. 2013 Feb;104(2):70-2. Italian. doi: 10.1701/1241.13708. PMID: 23535961.
22: Millet B, Jaafari N. Traitement du trouble obsessionnel compulsif [Treatment of obsessive-compulsive disorder]. Rev Prat. 2007 Jan 15;57(1):53-7. French. PMID: 17432002.
23: Wichowicz HM, Cubała WJ, Sławek J. Wilson's disease associated with delusional disorder. Psychiatry Clin Neurosci. 2006 Dec;60(6):758-60. doi: 10.1111/j.1440-1819.2006.01592.x. PMID: 17109711.
24: das Neves MC, Mendes MF, de Oliveira AJ, Viana EM, de Guadalupe A, de Barros HL, Hallak JE, Siqueira JM, Salgado JV. Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy. Epilepsy Behav. 2006 Nov;9(3):532-4. doi: 10.1016/j.yebeh.2006.07.015. Epub 2006 Aug 28. PMID: 16935566.
25: Hallak JE, Dursun SM, Guarnieri R, Almeida E, Rezeck K, Crippa JA, Sakamoto AC, Zuardi AW, Deakin JF. Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy. J Psychopharmacol. 2003 Sep;17(3):350-1. doi: 10.1177/02698811030173020. PMID: 14513930.
26: Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology. 2000 Sep 26;55(6):795-9. doi: 10.1212/wnl.55.6.795. PMID: 10993998.